Temporal expression of urokinase type plasminogen activator, tissue type plasminogen activator, plasminogen activator inhibitor type 1 in rhesus monkey corpus luteum during the luteal maintenance and regression

被引:24
|
作者
Liu, K
Liu, YX
Hu, ZY
Zou, RY
Chen, YJ
Mu, XM
Ny, T
机构
[1] CHINESE ACAD SCI, INST ZOOL, STATE KEY LAB REPROD BIOL, BEIJING 100080, PEOPLES R CHINA
[2] UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN
关键词
corpus luteum; rhesus monkey; urokinase-type plasminogen activator; tissue-type plasminogen activator; plasminogen activator inhibitor type 1;
D O I
10.1016/S0303-7207(97)00152-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Proteolytic activity generated by the plasminogen activator (PA) system has been associated with many biological processes. Using a pregnant mare serum gonadotropin (PMSG)/human chorionic gonadotropin (hCG)-induced rhesus monkey corpus luteum (CL) model, we have studied how urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor type 1 (PAI-I), are temporally expressed in CL of rhesus monkey at the luteotropic and luteolytic periods. Slot blot analysis and in situ hybridization were performed to analyze the expression and distribution of uPA and PAI-I messenger RNA (mRNA). Fibrin overlay was used to detect uPA and tPA activities. We found that uPA is the dominating PA in luteotropic CL in the monkey. Abundant expression of PAI-1 mRNA was detected. The highest expression of uPA and PAI-1 mRNA was observed at the luteotropic period, while their expression decreased approximate to 50% at early luteal regression defined by considerably decreased serum progesterone levels, and remained at very low levels al the late stage of luteal regression. We also observed an increased tPA activity at the time of luteal regression. Moreover, the exogenous tPA could inhibit the progesterone production in cultured luteal cells from 13-day-old monkey CL. We also used LH receptor mRNA expression as a mark for the luteal phases. A highly expressed, evenly distributed LH receptor mRNA was detected in CL during the luteotropic phase, while its expression decreased al day 13 coinciding with the reduction of progesterone production. We conclude that proteolysis mediated by uPA and regulated by PAI-I may play a role in the luteal maintenance, while tPA may participate in the luteal regression in the rhesus monkey. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 50 条
  • [41] Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure
    Wang, YM
    Pratt, JR
    Hartley, B
    Evans, B
    Zhang, LN
    Sacks, SH
    KIDNEY INTERNATIONAL, 1997, 52 (02) : 371 - 377
  • [42] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [43] Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis
    Sirén, V
    Kauhanen, P
    Carpén, O
    Luther, M
    Lepäntalo, M
    Vaheri, A
    Lassila, R
    BLOOD COAGULATION & FIBRINOLYSIS, 2003, 14 (04) : 369 - 377
  • [44] Urokinase-type plasminogen activator and plasminogen activator inhibitor induction by etoposide in a glioblastoma cell strain
    Matulic, M
    Brdar, B
    FOOD TECHNOLOGY AND BIOTECHNOLOGY, 2002, 40 (01) : 1 - 7
  • [45] Domain-domain interactions in hybrids of tissue-type plasminogen activator and urokinase-type plasminogen activator
    Bakker, AHF
    Nieuwenbroek, NME
    Verheijen, JH
    PROTEIN ENGINEERING, 1995, 8 (12): : 1295 - 1302
  • [46] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND TISSUE-TYPE PLASMINOGEN ACTIVATOR-PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 COMPLEX ARE RECOGNIZED BY DIFFERENT RECEPTOR SYSTEMS IN THE LIVER
    KUIPER, J
    OTTER, M
    VANZONNEVELD, AJ
    RIJKEN, DC
    VANBERKEL, TJC
    CIRCULATION, 1993, 88 (04) : 366 - 366
  • [47] Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator
    Stoop, A
    vanMeijer, M
    Horrevoets, AJG
    Pannekoek, H
    TRENDS IN CARDIOVASCULAR MEDICINE, 1997, 7 (02) : 47 - 51
  • [48] Effect of dsRNA on Mesangial Cell Synthesis of Plasminogen Activator Inhibitor Type 1 and Tissue Plasminogen Activator
    Woernle, Markus
    Roeder, Maximilian
    Sauter, Matthias
    Merkle, Monika
    Ribeiro, Andrea
    NEPHRON EXPERIMENTAL NEPHROLOGY, 2009, 113 (02): : E57 - E65
  • [49] Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men
    Beer, NA
    Jakubowicz, DJ
    Matt, DW
    Beer, RM
    Nestler, JE
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1996, 311 (05): : 205 - 210
  • [50] DEPRESSION OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ENHANCEMENT OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AS AN EXPRESSION OF LOCAL INFLAMMATION
    BROMMER, EJP
    DOOIJEWAARD, G
    DIJKMANS, BAC
    BREEDVELD, FC
    THROMBOSIS AND HAEMOSTASIS, 1992, 68 (02) : 180 - 184